Holen Sie sich die Stockscreener-App
192.95
0.16%
0.0888
Revolution Medicines Inc Aktie (RVMD) Neueste Nachrichten
Revolution Medicines (RVMD) Deepens RAS(ON) Bet With Breakthrough PDAC Combo – But Is Risk Repricing? - Yahoo Finance
AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib - markets.businessinsider.com
Form 4 Revolution Medicines Inc For: 22 September By Investing.com - Investing.com Canada
Revolution Medicines (RVMD) Wins FDA Breakthrough Status For RASONQUE - Yahoo Finance
Revolution Medicines (NASDAQ: RVMD) director plans stock sale from option exercise - Stock Titan
Here's How Much $1000 Invested In Revolution Medicines 5 Years Ago Would Be Worth Today - Benzinga
Illinois grew the science behind a breakthrough cancer drug — but couldn’t hold onto the company - Crain's Chicago Business
RVMD Maintained by B of A Securities -- Price Target Raised to $265 - GuruFocus
Client Revolution Medicines Secures 672,000-Square-Foot Redwood City Lease in former Google Space - Procopio
Revolution Medicines, Inc. (RVMD) Stock Analysis: A Promising 31.56% Upside in the Precision Oncology Space - DirectorsTalk Interviews
Revolution Medicines, Inc.(NasdaqGS: RVMD) added to FTSE All-World Index - marketscreener.com
This Insider Has Just Sold Shares In Revolution Medicines - simplywall.st
Revolution Medicines chief development officer sells $67,940 in stock By Investing.com - Investing.com South Africa
Revolution Medicines Senior Advisor Executes Stock Sales via 10b5-1 Plan to Cover RSU Taxes - Kalkine Media
Revolution Medicines officer sells $353,449 in shares By Investing.com - Investing.com Nigeria
Revolution Medicines’ senior advisor sells $1.1m in stock By Investing.com - Investing.com South Africa
Revolution Medicines CFO Jack Anders sells $807,513 in stock By Investing.com - Investing.com Australia
Revolution Medicines’ Jeff Cislini sells $670k in common stock By Investing.com - Investing.com Australia
Revolution Medicines CEO Mark Goldsmith sells $2.78m in stock - Investing.com
Revolution Medicines’ Jeff Cislini sells $670k in common stock - Investing.com
Revolution Medicines COO Margaret Horn sells $989,612 of common stock By Investing.com - Investing.com Nigeria
Revolution Medicines CFO Jack Anders sells $807,513 in stock - Investing.com
Revolution Medicines CEO Mark Goldsmith sells $2.78m in stock By Investing.com - Investing.com Canada
Revolution Medicines (RVMD) exec sells 1,774 shares, keeps 39,575 RSUs - Stock Titan
Revolution Medicines (RVMD) legal chief makes pre-set stock sale for taxes - Stock Titan
Revolution Medicines (RVMD) insider adds new sale after multimillion-dollar trades - Stock Titan
Revolution Medicines Just Hit a Major Milestone. Is the Stock a Buy? - The Globe and Mail
Revolution Medicines slips as investors weigh insider sale filings after recent regulatory wins - quiverquant.com
Advancing RAS(ON) Inhibition in Metastatic Pancreatic Cancer-Revolution Medicines - Oncodaily
Revolution Medicines’ (RVMD) Promising Clinical Results Signal Potential Paradigm Shift - Yahoo Finance
Revolution Medicines senior advisor Stephen Kelsey disposes of $18.7m in shares - Investing.com
Officer at Revolution Medicines (RVMD) plans 331-share sale - Stock Titan
Revolution Medicines officer plans $484K sale | RVMD SEC FilingForm 144 - Stock Titan
After $18.7M stock sale, Revolution Medicines (RVMD) officer files notice for another RSU share sale - Stock Titan
Officer at Revolution Medicines (NASDAQ: RVMD) plans 4,830-share stock sale after RSU vesting - Stock Titan
Over $16M in recent stock sales as Revolution Medicines (NASDAQ: RVMD) filer Mark A. Goldsmith plans another trade - Stock Titan
Revolution Medicines (RVMD) officer lines up another stock sale - Stock Titan
Revolution Medicines (NASDAQ: RVMD) insider plans sale of 3,939 shares - Stock Titan
Revolution Medicines’ chief commercialization officer Mancini sells $3.15m - Investing.com
Revolution Medicines to anchor former Google campus as Silicon Valley office market shifts - The Business Journals
A pancreatic cancer drug gets FDA breakthrough status. Its combo is still being tested. - Stock Titan
Revolution Medicines, Inc. (RVMD) Stock Analysis: A Promising 23.28% Upside in the Biotech Sector - DirectorsTalk Interviews
Revolution Medicines (RVMD) exec exercises options, sells stock - Stock Titan
(RVMD) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Revolution Medicine’s $39,800-Monthly Cancer Drug Puts Access In Focus — CEO Goldsmith Expects Insurers To Move ‘Swiftly’ To Provide Coverage - Stocktwits
ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death - Stocktwits
Revolution Medicines director Lorence Kim sells $3.58m in stock By Investing.com - Investing.com South Africa
Revolution Medicines (RVMD) Gets its First Approved Drug, and the Market Shrugs - Yahoo Finance
Abu Dhabi Investment Council Co P.J.S.C's Revolution Medicines Inc(RVMD) Holding History - GuruFocus
Revolution Medicines (NASDAQ: RVMD) officer plans multi-million stock option share sale - Stock Titan
Verastem CSO Pachter: The First RAS Drug Is a Floor, Not a Ceiling - finance.biggo.com
Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Revolution Medicines director Lorence Kim sells $3.58m in stock - investing.com
Revolution Medicines Director Lorence H. Kim Sells 14,090 Shares via Revocable Trust Under 10b5-1 Plan - Kalkine Media
Planned multimillion stock sale at Revolution Medicines (RVMD) - Stock Titan
Revolution Medicines Got a ‘Miracle’ Cancer Drug Approval. Wall Street Wants More. - Barron's
RVMD - Finviz
Morgan Stanley Initiates Overweight on RVMD, Highlighting RAS Pi - GuruFocus
Revolution a new overweight at Morgan Stanley on RAS-targeted oncology franchise - Seeking Alpha
RVMD Initiated Coverage by Morgan Stanley -- Rating Set to Overw - GuruFocus
RVMD Maintained by Stifel -- Price Target Raised to $230 - GuruFocus
Stifel Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $230 - Moomoo
Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial - The Manila Times
0.99%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):